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Role of mast cells in the development of renal fibrosis: Use of
mast cell–deficient rats.
Background. Recent clinical studies have shown that the
number of interstitial mast cells increases in various types of
renal disease and correlates well with the magnitude of inter-
stitial fibrosis. The present study was conducted to assess the
role of mast cells in renal fibrosis by examining an experimen-
tal glomerular disease.
Methods. A rat model of chronic glomerular disease,
puromycin aminonucleoside-nephrosis, was induced in mast
cell–deficient (Ws/Ws) and normal (+/+) rats.
Results. The area of interstitial fibrosis was widely distributed
at 6 weeks in both groups of rats; however, unexpectedly, the
area of interstitial fibrosis was greater in Ws/Ws rats than in +/+
littermates. Biochemical analysis of the hydroxyproline content
confirmed the more severe fibrosis in the Ws/Ws rats. The num-
ber of mast cells increased in both Ws/Ws and +/+ rats, con-
comitant with the development of interstitial fibrosis, but was
confirmed to be lower in Ws/Ws than in +/+ rats. There were
no differences in the numbers of interstitial macrophages and
T lymphocytes between the two groups. Reverse transcription-
polymerase chain reaction analysis of cytokine expression re-
vealed that the level of mRNA for transforming growth factor-
b (TGF-b), a potent profibrotic cytokine, was higher in Ws/Ws
rats. In addition, heparin, one of the major components of mast
cells, inhibited the expression of TGF-b mRNA in rat fibrob-
lasts in culture.
Conclusion. These results suggest that mast cells do not
play a major role in the pathogenesis of interstitial fibrosis in
puromycin aminonucleoside nephrosis. Rather, they might be
protective or ameliorative in this model through the inhibition
of TGF-b production by heparin, and possibly in other models
and also in humans.
Mast cells are known to be immune-effector cells that
augment inflammatory reactions. It is widely accepted
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that mast cells are involved in a number of allergic in-
flammatory diseases as well as in host defense against
pathogens. In addition, several lines of evidence suggest
that mast cells may participate in fibrotic processes. Mast
cells are found in fibrogenic lesions in various tissues in
human diseases, such as pulmonary fibrosis [1, 2], hep-
atic cirrhosis [3, 4], scleroderma [5, 6], and keloid [7].
Mast cells serve as a rich source of several mediators
[8], including histamines, proteoglycans, and proteolytic
enzymes (proteases), as well as a number of cytokines
[9], some of which are reported to be mitogenic [10] and
chemotactic [11] for fibroblasts, and to stimulate the pro-
duction of the extracellular matrix (ECM) by fibroblasts
[9, 10, 12]. Furthermore, mast cells themselves produce
components of the ECM [13]. Therefore, for these rea-
sons they are considered to play a profibrogenic role in
the above-mentioned diseases.
In recent years, mast cells were shown to be present
in the interstitial area of human renal biopsy tis-
sues from patients with various renal diseases, such as
IgA nephropathy [14–16], rapidly progressive glomeru-
lonephritis [17], focal and segmental glomeruloscle-
rosis [15], diabetic nephropathy [15, 18], and kidney
graft rejection [16, 19, 20]. Furthermore, the num-
ber of interstitial mast cells in these glomerular dis-
eases correlates well with the degree of interstitial
fibrosis. Tubulointerstitial lesions including interstitial fi-
brosis are considered to be prognostic features of various
glomerular diseases; regardless of its primary causes, de-
creased renal function correlates most closely with patho-
logic changes in the tubulointerstitium, which include
interstitial fibrosis, tubular atrophy, and loss of peritubu-
lar capillaries [21, 22]. Based on these observations, mast
cells are suggested to contribute to the renal deterioration
in glomerular diseases by inducing interstitial fibrosis [14,
15, 17]. However, there have been no studies that directly
show the involvement of mast cells in the pathogenesis
of interstitial fibrosis in the kidney.
To elucidate the role of mast cells in the inter-
stitial fibrosis in progressive glomerular diseases, we
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investigated the accumulation of mast cells in an animal
model of glomerular disease that is accompanied by inter-
stitial fibrosis and renal deterioration. Furthermore, we
utilized mast cell–deficient Ws/Ws rats to test if mast cells
contribute to the development of the interstitial fibrosis.
Ws/Ws rats have very few mast cells in their skin and other
tissues [less than 1% of the number in control (+/+) lit-
termates] because of a small deletion in the tyrosine ki-
nase domain of the c-kit gene [23–25]. Unexpectedly, in
this study we found that the degree of interstitial fibrosis
was more severe in Ws/Ws rats than in the control litter-
mates, suggesting that mast cells do not contribute to the
development of interstitial fibrosis in this model. Rather,
they may actually play a beneficial role in the process of
fibrosis in the kidney.
METHODS
Animal model
Puromycin aminonucleoside (PAN) nephrosis model
was induced in male mast cell–deficient Ws/Ws and their
normal +/+ littermates (Japan SLC; Hamamatsu, Japan,
N = 12 each), weighing 140 to 160 g, by the method of
Jones et al [26], with slight modifications. In brief, left
unilateral nephrectomy through a flank incision was per-
formed on each rat under sodium pentobarbital (45 mg/kg
body weight) anesthesia. Five days after the nephrectomy,
the rats received an intraperitoneal (i.p.) injection of PAN
(Sigma Chemical Co., St. Louis, MO, USA) dissolved in
0.9% saline (15 mg/mL) and given at a dose of 15-mg/100 g
body weight. Second, third, and fourth doses of PAN
(4.3 mg/100 g body weight, i.p.) were administered at 3, 4,
and 5 weeks, respectively, after the initial dose. Control
animals did not receive any surgical procedures or injec-
tions (N = 10 each). All animals were maintained on a
standard rat diet and had free access to water throughout
the course of the experiment. The animals were housed
individually in metabolic cages to obtain 24-hour urine
once every week. They were sacrificed sequentially at 2
(N = 5 each) and 6 weeks (N = 5 each except for N = 4 for
PAN-injected Ws/Ws rats; see below) after the initial dose
of PAN, namely, 1 week after the first and the last injec-
tions, respectively. Three of the PAN-injected Ws/Ws rats
and 2 of the PAN-injected +/+ rats died of chronic renal
failure by 6 weeks. These rats were found dead in their
cages in the morning, and thus their kidneys could not be
used for histologic studies. These animals were excluded
from the subsequent analysis. At sacrifice, blood samples
were collected by heart puncture under anesthesia with
diethylether. The kidneys were perfused via the abdom-
inal aorta with ice-cold saline, and pieces of renal tissues
were fixed in 10% buffered formalin or periodate-lysine-
paraformaldehyde (PLP) solution. Pieces of renal cortex
were also used for RNA preparation and hydroxyproline
analysis (see below). Urinary protein was quantified by
the biuret method. Levels of blood urea nitrogen (BUN)
were measured with a kit designed for clinical use (Wako
Pure Chemical Industries, Osaka, Japan).
Kidney tissue preparation
The kidney tissues fixed in 10% buffered formalin
were embedded in paraffin, sectioned, and stained with
hematoxylin and eosin, periodic acid-Schiff (PAS), or
Masson trichrome. The degree of interstitial fibrosis was
semiquantitatively analyzed by inspection of Masson
trichrome–stained sections and graded on a scale of 0
to 3 as follows: (0), no apparent damage; (1) mild dam-
age, with lesions involving less than 5% of the cortex; (2)
moderate damage, involving 5% to 20% of the cortex;
and (3) severe damage, involving more than 20% of the
cortex. Pieces for cryostat sectioning were fixed in PLP
solution for 4 hours, washed several times in phosphate-
buffered saline (PBS) containing 7% sucrose, embedded
in Tissue-Tek OCT compound (Sakura Finetek, Torrance,
CA, USA), and snap-frozen.
Immunohistochemical study
To block endogenous peroxidase activity, we treated
sections of frozen or paraffin-embedded kidney tissues
with methanol containing 0.6% hydrogen peroxide for
15 minutes and then washed them with PBS. They were
stained by the standard avidin-biotin peroxidase tech-
nique with sheep antirat mast cell protease (RMCP) I
(mast cell–specific antibody; Moredun, Scotland, UK),
mouse monoclonal antibody ED-1 (specific for rat mono-
cytes/macrophages), W3/25 (CD4+ cells), or OX8 (CD8+
cells) at 4◦C overnight. The sections were incubated with
the corresponding second antibodies, biotinylated don-
key antisheep IgG or horse antimouse IgG, and stained
with the reagents of an ABC staining kit (Vector Labo-
ratories, Inc., Burlingame, CA, USA). Sections were also
stained with horseradish peroxidase–conjugated mouse
antihuman a-smooth muscle actin (a−SMA, a marker
for myofibroblasts) monoclonal antibody (Dako Corp.,
Carpinteria, CA, USA). All sections were then de-
veloped with 3, 3′-diaminobenzidine solution as chro-
mogen and counterstained with methylgreen. With the
aid of a 10 × 10 eyepiece grid, the numbers of mono-
cytes/macrophages, CD4+, and CD8+ cells in the intersti-
tium were counted manually in 6 random nonoverlapping
cortical fields (×400) of sections made from each exper-
imental animal. RMCP I–positive interstitial mast cells
were also counted in 20 random cortical fields (×100).
The results of cell counting were expressed as the num-
ber per square millimeter.
Cell cultures
A cell line of renal fibroblasts (NRK49F) derived
from rat kidney was obtained from The European
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Table 1. Nucleotide sequences of the polymerase chain reaction (PCR) primers, the expected sizes of the amplified products, annealing
temperature, and cycle numbers of PCR reactions
Annealing
Primers Product temperature Cycles
RMCP II 5′ primer 5′-ACGAAAGTTACAACTCCGTTC-3′ 475 bp 60◦C 32
3′ primer 5′-GTGTCTCAAGCAGGTCAGG-3′
RMCP V 5′ primer 5′-GTCTATAACCGTCCTCCTAG-3′ 381 bp 54◦C 38
3′ primer 5′-TTTTGCATCTTCTTGGGGTTG-3′
RMCP VIII 5′ primer 5′-GGCCATCCTACCAGTCAACAC-3′ 341 bp 60◦C 30
3′ primer 5′-CACCATTGAGTTGAGCTTTGCG-3′
GAPDH 5′ primer 5′-GGGAGCCAAAAGGGTCATCATCTC-3′ 516 bp 64◦C 18
3′ primer 5′-CCATGCCAGTGAGCTTCCCGTTC-3′
All of the PCR reactions were performed as described in the Methods section.
Collection of Cell Cultures (Salisbury, UK) and main-
tained in Dulbecco’s modified Eagle’s medium (Invitro-
gen, Grand Island, NY, USA) supplemented with 10%
fetal calf serum (FCS), glutamine, and nonessential
amino acid equilibrated with 5% CO2-95% air at 37◦C.
For experiments, cells grown to 80% confluence in
100-mm dishes were exposed to fresh medium with or
without 100 lg/mL heparin (sodium salt; Sigma) for
6 hours and then used for RNA preparation.
Reverse transcription-polymerase chain
reaction (RT-PCR)
Total RNA fractions were prepared from pieces
of renal cortex or cultured cells by the guanidinium
thiocyanate-phenol-chloroform method [27], and 5 lg of
RNA was reverse-transcribed by use of oligo(dT) primers
in 20 lL of buffer as previously described [28]. For the
analysis of levels of mRNA for RMCPs II, V, and VIII,
1 lL of this reaction mixture containing the cDNA was
amplified by PCR in 50 lL of 10 mmol/L Tris-HCl (pH
9.0) containing 50 mmol/L KCl, 1.5 mmol/L MgCl2, 5′ and
3′ primers (Table 1), and Taq DNA polymerase (Promega,
Madison, WI, USA). Aliquots were electrophoresed on
a 2% agarose gel and visualized with ethidium bromide
under ultraviolet illumination. For the quantitative mea-
surement of cytokine mRNA levels, real-time PCR was
performed by using an ABI PRISM 7700 Sequence De-
tector and TaqMan Pre-Developed Assay Reagents
for Gene Expression Quantification System (Applied
Biosystems, Foster City, CA, USA). Using multiple re-
porter dyes, we assayed the mRNA levels of each cytokine
and endogenous control (GAPDH) in the same tube and
expressed cytokine mRNA levels as the ratio relative to
the endogenous control.
Hydroxyproline analysis
The amount of hydroxyproline in the renal cortex
was measured according to Kivirikko et al [29] as an
index of collagen content. At sacrifice, pieces of re-
nal cortex for the hydroxyproline assay were weighed,
snap-frozen in liquid nitrogen, and stored at −80◦C for
subsequent use. The samples were hydrolyzed in 1 mL
of 6N hydrochloric acid at 110◦C for 18 hours in tightly
capped tubes. After the hydrolysates had been neu-
tralized with sodium hydroxide, their hydroxyproline
content was assessed colorimetrically at 560 nm with
p-dimethylaminobenzaldehyde. Results were expressed
as ng per mg wet renal cortex.
Statistical analysis
All values were expressed as the mean ± SD. Data were
analyzed by the Mann-Whitney U test, and a difference
with a value of P < 0.05 was considered to be statistically
significant.
RESULTS
PAN nephrosis in Ws/Ws and +/+ rats
In PAN nephrosis model induced by uninephrectomy
and subsequent administration of PAN, increases in uri-
nary protein excretion and BUN level were observed in
both mast cell–deficient Ws/Ws and their control (+/+)
littermates; there was no difference in either parameter
between the two groups (Fig. 1). At 6 weeks, the level of
urinary protein excretion markedly decreased because of
the loss of functioning nephrons (end-stage renal failure).
Renal fibrosis induced in Ws/Ws and +/+ rats by PAN
Interstitial fibrosis occurred in both PAN-treated
Ws/Ws and +/+ rats at 2 weeks at the border of the cortex-
medulla. A significant expansion of the fibrotic area was
observed at 6 weeks in both strains. Unexpectedly how-
ever, the fibrosis was more severe in the Ws/Ws rats than
in their +/+ littermates (Fig. 2). No obvious fibrosis was
observed in the control animals. The magnitude of fibrosis
was semiquantitatively determined with light microscopy
(Fig. 3). The degree of fibrosis was similar in both groups
at 2 weeks, but was greater in Ws/Ws rats than in +/+ rats
at 6 weeks.
To confirm these histologic results, we measured the
hydroxyproline content in the renal cortex (Fig. 4). At
2 weeks, although the content of this collagen marker
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Fig. 1. Clinical course of puromycin aminonucleoside (PAN) nephro-
sis in Ws/Ws and +/+ rats. Blood urea nitrogen (A), urinary protein
excretion (B). Control +/+ (); Control Ws/Ws ( ); PAN-treated +/+
( ); PAN-treated Ws/Ws rats ().
in PAN-treated animals was slightly higher than that in
control animals, the difference was not statistically sig-
nificant; and the level was similar in PAN-treated Ws/Ws
and +/+ rats. At 6 weeks, the content was significantly
greater in PAN-treated animals than in control animals.
Moreover, the level in the PAN-treated Ws/Ws rats was
significantly higher than that in the PAN-treated +/+ rats.
Thus, the fibrotic changes in the interstitium assessed by
both histologic and biochemical methods were greater in
Ws/Ws rats than in their +/+ littermates.
Interstitial mast cells in PAN-induced nephrosis
Mast cells were immunohistochemically identified by
their immunoreactivity, indicating the presence of RMCP
I, a specific marker for mast cells [30, 31]. An almost
complete absence of mast cells in the skin of Ws/Ws rats
was confirmed by immunostaining for RMCP I (data not
shown). Practically no mast cells were detectable in the
kidney of control Ws/Ws and +/+ rats. However, in the
kidney tissues of PAN-treated +/+ rats, mast cells were
observed in the interstitium, where they showed a scat-
tered distribution (Fig. 5A). Most were localized in the
peritubular region (Fig. 5B).
To confirm the increase in the number of mast cells in
the kidney, we also examined mRNA levels of other spe-
cific markers for mast cells (i.e., RMCPs II, V, and VIII).
By RT-PCR analysis, mRNAs for all of these proteases
were consistently found in disease-induced rats, but not
in control rats, by the experimental procedures used
(Fig. 6).
The time-kinetics of the number of interstitial mast
cells determined by immunohistochemistry is illustrated
in Figure 7. After administration of PAN, the number
of mast cells increased significantly in both Ws/Ws and
+/+ rats, but was lower in the former than in the lat-
ter. While the number of mast cells gradually increased
in PAN-treated +/+ rats with the expansion of the in-
terstitial fibrosis, the number in PAN-treated Ws/Ws rats
decreased with the continued expansion. The number in
PAN-treated Ws/Ws rats was one half at 2 weeks and one
fifth at 6 weeks compared with that in the PAN-treated
+/+ rats.
Other interstitial cells in PAN-induced nephrosis
Because thymocytes are c-kit–positive cells, the defect
in c-kit carried by Ws/Ws rats could potentially affect
T-cell development, although there have been no reports
showing such T-cell deficits. It is also known that myofi-
broblasts express c-kit [32]. To clarify the influence of the
c-kit deletion in these types of cell in the kidney of Ws/Ws
rats, we examined the levels of monocytes/macrophages,
CD4−, CD8−, and a−SMA–positive cells in the inter-
stitium (Table 2). Low numbers of these types of cells
were detected in the interstitium of the control animals.
After the disease induction, their numbers increased in
both Ws/Ws and +/+ rats, but there were no differences
in them between the two strains. Most of the mono-
cyte/macrophages and CD4− and CD8– positive cells
were found in the interstitial lesion in clusters, especially
in the area around glomeruli and disrupted tubuli, and
the localization was different from that of the mast cells.
Cytokine mRNA levels in renal cortex
To investigate the possible mechanism for the increase
in fibrosis in these Ws/Ws rats, we measured mRNA levels
of cytokines that might affect the progression of fibrosis.
As shown in Figure 8, the levels of mRNA for two poten-
tially profibrotic cytokines, TGF-b and interleukin (IL)-4,
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Fig. 2. Representative histologic changes in the kidney in puromycin aminonucleoside (PAN) nephrosis. Kidney tissues were obtained at 6 weeks
from PAN-treated +/+ rats (A) and PAN-treated Ws/Ws rats (B). Masson-trichrome staining. Original magnification ×100.
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Fig. 3. Semiquantification of the fibrotic interstitium in puromycin
aminonucleoside (PAN) nephrosis. Kidney tissues were obtained at
2 and 6 weeks from PAN-treated +/+ and Ws/Ws rats. ∗P < 0.05.
were higher in the Ws/Ws rats than in the +/+ ones. The
differences between the two groups in the level of TGF-b
mRNA at 2 weeks, and in that of IL-4 mRNA at 6 weeks,
were statistically significant. There were no differences
in mRNA levels of IL-2, IL-10, and interferon (IFN)-c
in the renal cortex between the two strains. These results
suggest that the enhanced production of TGF-b and/or
IL-4 in Ws/Ws rats may have caused the enhanced fibrosis
in the kidney.
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Fig. 4. Hydroxyproline content in renal cortex of rats with puromycin
aminonucleoside (PAN) nephrosis. Control +/+ (); control Ws/Ws
( ); PAN-treated +/+ ( ); PAN-treated Ws/Ws rats (). ∗P < 0.05;
∗∗P < 0.01.
Effect of heparin on the expression of TGF-b1 mRNA
in renal fibroblast in culture
Although mast cells have been shown to produce TGF-
b and IL-4 in culture [9], they also produce other cy-
tokines and factors that may modulate the production of
these cytokines by other types of cells. Heparin is a major
component stored in secretory granules of mast cells and
is known to influence cytokine production in culture [33].
Therefore, using a cell line of interstitial fibroblasts de-
rived from normal rat kidney, we investigated if heparin
could influence the production of TGF-b in culture. As
shown in Figure 9, the expression of TGF-b mRNA in
renal fibroblast was inhibited by heparin.
DISCUSSION
In progressive human glomerular diseases, regard-
less of their type, the number of interstitial mast cells
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Fig. 5. Immunostaining for rat mast cell protease (RMCP) I, a specific marker for mast cell, in puromycin aminonucleoside (PAN) nephrosis.
Representative kidney sections obtained at 6 weeks from PAN-treated +/+ rats are shown. RMCP I-positive cells with a scattered distribution are
seen in the interstitium (A). These cells are mostly located in the peritubular region (B). Original magnification, ×100 (A) and ×200 (B).
RMCP II
RMCP V
RMCP VIII
GAPDH
– – – + + +
Nephrectomy and PAN injection
Fig. 6. Expression of mRNA for rat mast cell proteases (RMCPs) II,
V, and VIII. RNA extracted from 3 animals of each group [2-week
puromycin aminonucleoside (PAN)-treated +/+ rats and control +/+
rats] was used for reverse transcription-polymerase chain reaction (RT-
PCR) analysis. Each lane represents the mRNA expression of each
animal. The GAPDH band is shown as the internal control.
increases as interstitial fibrosis expands [14, 15, 17]. The
present study has demonstrated that in PAN nephrosis,
a rat model of progressive glomerular disease, the num-
ber of interstitial mast cells also increased concomitant
with the expansion of interstitial fibrosis. We also found
that the number of interstitial mast cells increased in the
crescentic glomerulonephritis model in Wistar Kyoto rats
(our unpublished observations). These results indicate
that, like in humans, mast cells accumulate in the inter-
stitial area in progressive renal diseases in rats when in-
terstitial fibrosis develops.
Because PAN nephrosis can be induced in any strain
of rat, using mast cell–deficient Ws/Ws rats, we then in-
vestigated the suggested causal link between mast cell
accumulation and interstitial fibrosis. Unexpectedly, in-
terstitial fibrosis was markedly worse in these rats.
Although mast cells were not completely absent in the
diseased kidney of Ws/Ws rats, their number at 6 weeks
in PAN-treated Ws/Ws rats was approximately one fifth
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Fig. 7. Numbers of interstitial rat mast cell protease (RMCP) I-positive
cells in puromycin aminonucleoside (PAN) nephrosis. Control +/+ ();
control Ws/Ws ( ); PAN-treated +/+ ( ); PAN-treated Ws/Ws rats ().
∗P < 0.05.
of that in the PAN-treated control littermates. Because
it was shown that the number of mast cells in the whole
body of Ws/Ws rats is decreased by aging [23], we consid-
ered that the decrease in the number of interstitial mast
cells from 2 to 6 weeks in the rats resulted from aging
and is irrelevant to the development of interstitial fibro-
sis. The observed interstitial mast cells in the Ws/Ws rats
may have resulted from the accumulation of the remain-
ing small number of mast cells from other parts of the
body [34]. In contrast, there were no differences between
the two strains in the levels of interstitial T lymphocytes
and myofibroblasts, two types of cell that could be af-
fected by the c-kit gene mutation in Ws/Ws rats. Taken
together, these results suggest that the reduction in the
number of interstitial mast cells in Ws/Ws rats resulted
in the exacerbation of interstitial fibrosis in this model.
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Table 2. Interstitial cells in +/+ and Ws/Ws rats at 6 weeks
Control PAN nephrosis
+/+ Ws/Ws +/+ Ws/Ws
ED-1 (monocytes/macrophages)a 83.8 ± 13.3 80.0 ± 10.6 570.0 ± 40.1 592.0 ± 46.3
W3/25 (CD4+ cells)a 157.4 ± 14.4 165.8 ± 11.8 593.9 ± 42.4 580.0 ± 36.0
OX8 (CD8+ cells)a 21.1 ± 10.3 16.6 ± 4.8 116.5 ± 12.7 112.8 ± 12.6
a-SMA (myofibroblast)b 1.2 ± 0.3 1.3 ± 0.3 11.6 ± 1.1 10.5 ± 3.3
a-SMA, alpha-smooth muscle actin.
aData are the numbers of interstitial cells per mm2 expressed as mean ± SD (N = 5).
bData are % interstitial positive area expressed as mean ± SD (N = 5).
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Fig. 8. Expression of cytokine mRNA levels in renal cortex of rats with puromycin aminonucleoside (PAN) nephrosis. Data are expressed as the
ratio to the internal control. PAN-treated +/+ ( ); PAN-treated Ws/Ws rats (). ∗P < 0.05.
It was demonstrated earlier that myofibroblast prolifera-
tion is paralleled by or precedes the development of inter-
stitial fibrosis in human and animal models [35], but the
result of the present study is not consistent with those pre-
vious studies. It could be possible that there is some un-
known effect that originated from the mutated c-kit gene
that changed the functions of myofibroblasts in Ws/Ws
rats. In addition, we cannot exclude the possibility that
the mutated c-kit gene causes other abnormalities than
mast cell deficiency, although there have been no reports
so far that show such defects in Ws/Ws rats except for
anemia in their early life [23].
Our present study using mast cell–deficient Ws/Ws is
the first one to our knowledge to reveal the role of mast
cells in renal fibrosis. There have been some earlier stud-
ies in which the involvement of mast cells in fibrosis of
lung [36, 37], liver [36, 38], and skin [39, 40] was examined
by using mast cell–deficient W/Wv mice and/or Ws/Ws
rats. Some of these studies showed no difference in the
magnitude of fibrosis between the mast cell–deficient an-
imals and their control +/+ littermates, which suggested
that mast cells do not appear to be necessary for the in-
duction of fibrosis. In the present study, our histologic and
biochemical analysis revealed that the fibrosis was more
severe in Ws/Ws rats than in +/+ littermates at 6 weeks
after the induction of PAN nephrosis. These data are con-
sistent with other studies on lung [36, 37] and liver [36]
fibrosis, which showed that the increase in the hydrox-
yproline content of the tissues of deficient animals was
greater than that in control +/+ littermates.
The mechanism by which greater renal interstitial fi-
brosis occurred in Ws/Ws rats with PAN nephrosis is
unclear. We investigated the possibility that levels of cy-
tokines that potentially enhance directly or indirectly the
progression of fibrosis are changed in Ws/Ws rats with
PAN nephrosis. The cytokines tested in this study in-
cluded Th1 and Th2 cytokines, the balance of which is sug-
gested to affect fibrotic changes [41]. Our results showed
that mRNA levels of TGF-b and IL-4 were higher in
Ws/Ws rats than in controls in the PAN nephrosis model,
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Fig. 9. Inhibition of expression of transforming growth factor (TGF)-
b1 mRNA by heparin. Rat renal fibroblasts were cultured in the absence
( ) or presence () of heparin for 6 hours. Data are expressed as mean
± SD of 5 samples.
suggesting that the deficiency of mast cells (i.e., in Ws/Ws
rats) may have caused an increase in their expression,
resulting in more fibrosis in the Ws/Ws rats.
Mast cells contain a variety of mediators that have been
shown to directly or indirectly affect the progression of
fibrosis in tissues [42]. Although mast cells have been
shown to produce TGF-b and IL-4 in culture [9], they
also produce other cytokines and factors that may modu-
late cytokine production by other types of cells. Heparin,
a major component stored in secretory granules of mast
cells, was shown to have effects on cell proliferation [43]
and cytokine production [33], both of which are involved
in the pathogenesis of fibrosis. Heparin was also shown to
inhibit DNA synthesis by human renal fibroblasts when
added alone, although it enhanced DNA synthesis when
added with tryptase, a proteolytic enzyme secreted by
mast cells [44]. The present study demonstrated that hep-
arin inhibited the gene expression of TGF-b , the most
potent fibrogenic cytokine, in renal fibroblasts in culture.
A recent study also demonstrated that heparin inhibited
the production of TGF-b by cultured human proximal
tubular epithelial cells, another source of the cytokine
in diseased kidney [45]. Therefore, it is conceivable that
heparin secreted from mast cells may inhibit TGF-b pro-
duction by these cells in the diseased kidney and that this
action may have contributed to the less fibrosis in the con-
trol +/+ littermates in the PAN nephrosis model. We also
tested the effect of heparin on IL-4 production by these
cells, but the production level was very low, and thus the
effect of heparin could not be detected (our unpublished
observation).
The results of the present study using mast cell–
deficient animals seem to be in conflict with a suggested
role of mast cells in renal diseases. The profibrogenic role
of mast cells has been proposed mostly based on histo-
logic observations of clinical samples and results of in
vitro studies using cultured cells [14–20, 44]. However,
the histologic studies only showed a correlation between
the two phenomena, mast cell accumulation and fibro-
sis, and do not provide evidence of a causal link between
them. In vitro studies, on the other hand, give data on the
potential effects of mast cells or their secretory compo-
nents on fibrosis, but do not provide information about
the overall effect of mast cells. Even if whole components
stored in mast cells or mast cells themselves are used in a
culture system, one cannot provide all cells and extracel-
lular circumstances of the kidney in the in vitro system.
Further studies are needed to elucidate the role of mast
cells in the mechanism of fibrosis, but we consider that
experiments using animal models as well as intervention
studies in humans will be necessary to assess the effect of
mast cells as a whole on fibrosis.
In the kidney of the animal models of glomerular
diseases we tested, mast cells were localized in a scat-
tered distribution in the interstitium, whereas interstitial
mononuclear cells (MNC), mostly consisting of mono-
cytes/macrophages and T lymphocytes, were present in
clusters. In human glomerular diseases on the other hand,
mast cells were restricted to the area of interstitial fibrosis
where only a few T lymphocytes and macrophages were
concomitantly present, but were rarely found in the in-
terstitial lesion where the influx of MNC was pronounced
(our unpublished observations). This interstitial influx of
MNC presumably precedes the interstitial fibrosis and
is suggested to be involved in the mechanism of fibrotic
changes [46]. Therefore, in consideration of these find-
ings, together with the results of the present study, it is
conceivable that mast cells are not involved in the devel-
opment of fibrosis because of their absence in prefibrotic
lesions in contrast to T lymphocytes or macrophages, but
are attracted in fibrotic lesion and possibly participate in
the attenuation or resolution of the fibrotic lesions. Un-
fortunately, in the rodent models it was rather difficult
to discriminate prefibrotic lesions from established areas
of fibrosis, probably because of the short duration and/or
acute inflammation after the disease onset.
CONCLUSION
In the present study, we investigated the role of
mast cells in the development of renal fibrosis by us-
ing mast cell–deficient rats. In human studies, mast cells
are thought to be one of the cell types contributing to
the interstitial fibrosis. However, it could be mentioned
from our data that mast cells are not simply fibrogenic.
Rather, they might have a potential to be protective or
2236 Miyazawa et al: Role of mast cells in renal fibrosis
ameliorative in this model and possibly in other models
and also in humans.
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